Protalix Biotherapeutics Stock Net Income
| PLX Stock | USD 1.69 0.01 0.60% |
Protalix Biotherapeutics fundamentals help investors to digest information that contributes to Protalix Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Protalix Stock. The fundamental analysis module provides a way to measure Protalix Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Protalix Biotherapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Income | 8.3 M | 8.7 M | |
| Net Income From Continuing Ops | 8.3 M | 8.7 M | |
| Net Loss | -13.4 M | -14.1 M | |
| Net Income Per Share | 0.12 | 0.13 | |
| Net Income Per E B T | 0.97 | 1.02 |
Protalix | Net Income |
Protalix Biotherapeutics Company Net Income Analysis
Protalix Biotherapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Protalix Biotherapeutics Net Income | 8.31 M |
Most of Protalix Biotherapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Protalix Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Protalix Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Protalix Biotherapeutics is extremely important. It helps to project a fair market value of Protalix Stock properly, considering its historical fundamentals such as Net Income. Since Protalix Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Protalix Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Protalix Biotherapeutics' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Protalix Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Protalix Biotherapeutics reported net income of 8.31 M. This is 97.56% lower than that of the Biotechnology sector and 88.13% lower than that of the Health Care industry. The net income for all United States stocks is 98.54% higher than that of the company.
Protalix Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Protalix Biotherapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Protalix Biotherapeutics could also be used in its relative valuation, which is a method of valuing Protalix Biotherapeutics by comparing valuation metrics of similar companies.Protalix Biotherapeutics is currently under evaluation in net income category among its peers.
Protalix Biotherapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Protalix Biotherapeutics from analyzing Protalix Biotherapeutics' financial statements. These drivers represent accounts that assess Protalix Biotherapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Protalix Biotherapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 48.7M | 105.8M | 36.7M | 66.4M | 120.2M | 114.2M | |
| Enterprise Value | 91.8M | 151.9M | 31.2M | 82.8M | 122.8M | 116.7M |
Protalix Fundamentals
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.1 | ||||
| Profit Margin | (0.39) % | ||||
| Operating Margin | (0.18) % | ||||
| Current Valuation | 102.72 M | ||||
| Shares Outstanding | 73.63 M | ||||
| Shares Owned By Insiders | 14.53 % | ||||
| Shares Owned By Institutions | 5.20 % | ||||
| Number Of Shares Shorted | 3.1 M | ||||
| Price To Earning | (1.23) X | ||||
| Price To Book | 3.81 X | ||||
| Price To Sales | 3.27 X | ||||
| Revenue | 65.49 M | ||||
| Gross Profit | 28.05 M | ||||
| EBITDA | 11.65 M | ||||
| Net Income | 8.31 M | ||||
| Cash And Equivalents | 17.11 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 26.28 M | ||||
| Current Ratio | 1.33 X | ||||
| Book Value Per Share | 0.46 X | ||||
| Cash Flow From Operations | (1.32 M) | ||||
| Short Ratio | 22.71 X | ||||
| Earnings Per Share | (0.15) X | ||||
| Price To Earnings To Growth | (0.10) X | ||||
| Target Price | 14.0 | ||||
| Number Of Employees | 208 | ||||
| Beta | 0.67 | ||||
| Market Capitalization | 124.44 M | ||||
| Total Asset | 84.43 M | ||||
| Retained Earnings | (381.55 M) | ||||
| Working Capital | 24.4 M | ||||
| Current Asset | 59.65 M | ||||
| Current Liabilities | 10.33 M | ||||
| Net Asset | 84.43 M |
About Protalix Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Protalix Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Protalix Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Protalix Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.